|Bid||65.78 x 800|
|Ask||66.24 x 800|
|Day's Range||58.25 - 67.86|
|52 Week Range||36.41 - 70.50|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||174.89|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.43|
Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held C Technologies, Inc. for approximately $240 million, comprised of $192 million in cash plus $48 million in Repligen common stock.
If you own shares in Repligen Corporation (NASDAQ:RGEN) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Volatility is considered to be a m...
Repligen Corp NASDAQ/NGS:RGENView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is moderately high for RGEN with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 27. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding RGEN are favorable, with net inflows of $2.53 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Repligen has grown product revenue 220% since 2014, but it trades at 70 times future earnings. What should investors make of that?
The most recent earnings update Repligen Corporation's (NASDAQ:RGEN) released in December 2018 indicated that the company experienced a substantial headwind with earnings declining by -41%. Below, I've laid out keyRead More...
Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. Repligen Corp had annual average EBITDA growth of 1.80% over the past five years. Warning! GuruFocus has detected 4 Warning Signs with RGEN.
Repligen (RGEN) delivered earnings and revenue surprises of 0.00% and 3.20%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Waltham, Massachusetts-based company said it had net income of 12 cents per share. Earnings, adjusted for one-time gains and costs, came to 21 cents per share. The results matched Wall Street expectations. ...
Record quarterly revenue of $51.9 million represents 25% year-over-year growth, and record annual revenue of $194.0 million represents 37% year-over-year growthOverall organic.
WALTHAM, Mass., Feb. 15, 2019 -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2018 financial results on.
Mid-caps stocks, like Repligen Corporation (NASDAQ:RGEN) with a market capitalization of US$2.4b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. Read More...
NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...
NEW YORK, Jan. 23, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Repligen (RGEN) is a pure-play supplier of bioprocessing technologies. It is a market leader in proteins (over 95% market share), where it has a near monopoly, explains Tyler Laundon, editor of Cabot Small-Cap Confidential.